Suspected Liver Injury and the Dilemma of Causality

Digestive Diseases and Sciences

Volumn 62, Issue 4, 2017, Pages 1095-1098

  Teschke, Rolf ^a   Eickhoff, Axel ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Causality assessment; Liver injury; OxyELITE Pro; RUCAM

Indexed keywords

ACUTE LIVER FAILURE; CAUSALITY; CHRONIC HEPATITIS B; DIET SUPPLEMENTATION; HUMAN; LETTER; LIVER CELL DAMAGE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; PRIORITY JOURNAL; CHEMICAL AND DRUG INDUCED LIVER INJURY;

CAUSALITY; CHEMICAL AND DRUG INDUCED LIVER INJURY; HUMANS;

EID: 85013031450     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-016-4442-5     Document Type: Letter

References (13)

1. Heidemann LA, Navarro VJ, Ahmad J, et al. Severe acute hepatocellular injury attributed to OxyELITE Pro: A case series. Dig Dis Sci. 2016;61:2741–2748. doi:10.1007/s10620-016-4181-7.
2. Teschke R, Schulze J, Eickhoff A, Wolff A, Frenzel C. Review article: mysterious Hawaii liver disease case—naproxen overdose as cause rather than OxyELITE Pro? J Liver Clin Res. 2015;2. http://www.jscimedcentral.com/Liver/liver-2-1013.pdf.
3. Teschke R, Schwarzenboeck A, Frenzel C, Schulze J, Eickhoff A, Wolff A. The mystery of the Hawaii liver disease cluster in summer 2013: a pragmatic and clinical approach to solve the problem. Ann Hepatol. 2016;15:91–119.
4. Teschke R, Eickhoff A. The Honolulu liver disease cluster at the Medical Center: its mysteries and challenges. Int J Mol Sci. 2016;17:476. doi:10.3390/ijms17040476.
5. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17:14. doi:10.3390/ijms17010014.
6. Hayashi PH. Drug-induced liver injury network causality assessment: criteria and experience in the United States. Int J Mol Sci. 2016;17:201. doi:10.3390/ijms17020201.
7. Sarges P, Steinberg JM, Lewis JH. Drug-induced liver injury: highlights from a review of the 2015 literature. Drug Saf. 2016;39:561–575. doi:10.1007/s4026401604278.
8. Frenzel C, Teschke R. Herbal hepatotoxicity: clinical characteristics and listing compilation. Int J Mol Sci. 2016;17:588. doi:10.3390/ijms17050588.
9. Klontz KC, DeBeck HJ, LeBlanc P, et al. The role of adverse event reporting in the FDA response to a multistate outbreak of liver disease associated with a dietary supplement. Pub Health Rep. 2015;130:526–532.
10. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug induced liver injury network prospective study: rationale, design, and conduct. Drug Saf. 2009;32:55–68.
11. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the RUCAM. Hepatology. 2010;51:2117–2126.
12. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of Idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49:2001–2009.
13. Navarro V, Khan I, Bjornsson E, et al. Liver injury from herbal and dietary supplements hepatology. Hepatology. 2016. doi:10.1002/hep.28813/epdf.